Anthony M. DiGiorgio, DO, MHA, an assistant professor of neurosurgery at the University of California, San Francisco (UCSF), expressed concerns about the 340B program during an appearance on the Healthcare Unfiltered podcast. Read More »
Heath Veuleman, a Healthcare Strategist for Seersucker Strategies, has expressed concerns about various hospital cost centers, including 340B profits, facility fees, provider taxes, and higher site-based Medicare payments. Read More »
Jennifer Riley, Executive Director of Patients Come First, expressed concerns about deceptive legal advertisements concerning FDA-approved medicines. Read More »
The Institute for Clinical and Economic Review (ICER) has released a white paper detailing strategies to enhance the affordability of GLP-1 obesity drugs, including the improvement of patent-quality review processes. Read More »
BPI Labs has announced its collaboration with Empower Pharmacy to challenge Eli Lilly's patent on tirzepatide. Read More »
Ken Paxton, the Attorney General for Texas, has accused Eli Lilly of using illegal kickbacks to influence prescriptions of its drugs for profit, potentially harming taxpayers and public health. Read More »
Shaun Noorian, CEO of Empower Pharmacy, said that recent findings by the U.S. Food and Drug Administration (FDA) indicate that efforts by the pharmaceutical industry to discredit compounding pharmacies were not rooted in safety concerns. Read More »
Shaun Noorian, CEO of Empower Pharmacy, emphasized the importance of compounded medications for personalized and affordable patient care. Read More »
The Iowa Board of Pharmacy has announced the filing of charges against FarmaKeio, a mail-order compounding pharmacy, citing violations of the federal Food, Drug and Cosmetics Act. Read More »
Marion Mass, a pediatrician and co-founder of Free2Care, has raised concerns about the misuse of the 340B Drug Pricing Program by large healthcare corporations. Read More »
David Balto, a former policy director at the Federal Trade Commission (FTC), has raised concerns about the 340B drug discount program, alleging that it is being manipulated by corporate hospital systems and large pharmacies to the detriment of... Read More »
Danea Horn, a researcher at the University of California, has indicated that physicians or their employer organizations might select patients requiring intensive pharmaceutical treatments to benefit from financial incentives under the 340B program. Read More »
The National Consumers League (NCL) has announced the results of a national Morning Consult poll, which reveals significant public support for comprehensive reforms to the 340B Drug Pricing Program. Read More »
Gerard Acloque, a doctor at The Florida Concierge Medicine & Wellness, expressed concerns over Eli Lilly's legal actions against compounding pharmacies and telehealth companies producing compounded Tirzepatide. Read More »
Craig Brockie, founder of Ultimate Health Solutions, has expressed concerns about the priorities of large pharmaceutical companies. Read More »
Shaun Noorian, CEO of Empower Pharmacy, said that the U.S. pharmaceutical industry distorts global drug markets through excessive lobbying and anti-competitive practices. Read More »
The National Library of Medicine has announced that compounded medications offer therapeutic alternatives for patients with unique medical needs that cannot be met by U.S. Food and Drug Administration (FDA)-approved drugs. Read More »
Centene Corporation (NYSE: CNC) announced that it has completed its acquisition of PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and treating rare diseases. Read More »
The U.S. Food and Drug Administration (FDA) recently issued the first emergency use authorization (EUA) allowing the Pfizer-BioNTech COVID-19 vaccine to be distributed in the U.S., according to a release by the FDA. Read More »
The Food and Drug Administration Advisory panel approved the Pfizer-BioNTech COVID-19 vaccine Dec. 10, greenlighting vaccination efforts for priority groups including frontline health care workers, pharmacists and residents at long-term care facilities, the American Pharmacists Association reports. Read More »
Alerts Sign-up
